These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 29940217

  • 1. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M, Mundin G, Sumner M.
    Eur J Pharm Sci; 2018 Sep 15; 122():125-133. PubMed ID: 29940217
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.
    Gunderson EW, Sumner M.
    J Addict Med; 2016 Sep 15; 10(2):124-30. PubMed ID: 26918662
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
    Larance B, Dietze P, Ali R, Lintzeris N, White N, Jenkinson R, Degenhardt L.
    Drug Alcohol Rev; 2015 Nov 15; 34(6):603-10. PubMed ID: 25950232
    [Abstract] [Full Text] [Related]

  • 7. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
    Butler SF, Black RA, Severtson SG, Dart RC, Green JL.
    J Subst Abuse Treat; 2018 Jan 15; 84():42-49. PubMed ID: 29195592
    [Abstract] [Full Text] [Related]

  • 8. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
    Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, White N, Degenhardt L.
    Drug Alcohol Depend; 2014 Mar 01; 136():21-7. PubMed ID: 24461476
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
    Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT.
    Clin Pharmacokinet; 2004 Mar 01; 43(5):329-40. PubMed ID: 15080765
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
    Dhagudu NK, Ambekar A, Agrawal A, Rao R, Mishra AK, Jain R, Singh S.
    Drug Alcohol Rev; 2020 Jul 01; 39(5):595-603. PubMed ID: 32162420
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
    Dong R, Wang H, Li D, Lang L, Gray F, Liu Y, Laffont CM, Young M, Jiang J, Liu Z, Learned SM.
    Drugs R D; 2019 Sep 01; 19(3):255-265. PubMed ID: 31197606
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
    Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, Blasey C, Sigmon S, Beebe KL.
    Addiction; 2013 Dec 01; 108(12):2141-9. PubMed ID: 23919595
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers.
    Nasser AF, Heidbreder C, Liu Y, Fudala PJ.
    Clin Pharmacokinet; 2015 Aug 01; 54(8):837-49. PubMed ID: 25603822
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
    Chiang CN, Hawks RL.
    Drug Alcohol Depend; 2003 May 21; 70(2 Suppl):S39-47. PubMed ID: 12738349
    [Abstract] [Full Text] [Related]

  • 20. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.
    Addiction; 2012 Jan 21; 107(1):142-51. PubMed ID: 21749526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.